This Research Topic is part of the Brief Research and Case Reports in Pharmacology series run across the sections focusing on new research of 2022.
This Research Topic focuses on high-quality brief case reports in Experimental Pharmacology and Drug Discovery research, reporting on all mainstream aspects of the field. It also covers complementary facets that are critical for a clear understanding of the current trends in the field and of the upcoming challenges. The collection aims to produce a resource for academics, professionals, and the general population.
Brief Research Report articles present original research and/or preliminary findings in a more succinct way, and with fewer details, than Original Research articles. Additionally, in line with the Frontiers ethos of publishing scientifically-sound discoveries, Brief Research Reports also encourage the submission of negative results and may report on the non-reproducibility of previously published results. Brief Research Reports articles are peer-reviewed, have a maximum word count of 4,000, and may contain no more than 4 Figures/Tables. These submissions aim to highlight unique findings to produce a succinct resource as a valuable tool for researchers.
This Research Topic will only accept Brief Research Report submissions within the field of Experimental Pharmacology and Drug Discovery; reports must be original with the aim to significantly advance the field to be considered. Topics could include, but are not limited, to the following:
1. mechanisms of drug action of approved and/or potential drug candidates, looking at interactions with receptors and/or other specific biological targets (including enzymes, ion channels, transporters, transcription factors etc.),
2. drug-biomolecule interactions of approved and/or potential drug candidates (including analysis of binding, transduction mechanisms, physiological responses, and pharmacokinetics at the molecular, cellular and organism levels),
3. modern drug discovery with respect to “small molecules” and biopharmaceuticals, such as target identification (high-throughput) screening and other lead-finding techniques, medicinal chemistry, pharmacokinetics, metabolism, and pharmacology of investigatory drugs, as well as
4. novel pharmacodynamic and pharmacokinetic mechanisms that may explain/predict clinical effects of approved drugs.
This Research Topic is part of the Brief Research and Case Reports in Pharmacology series run across the sections focusing on new research of 2022.
This Research Topic focuses on high-quality brief case reports in Experimental Pharmacology and Drug Discovery research, reporting on all mainstream aspects of the field. It also covers complementary facets that are critical for a clear understanding of the current trends in the field and of the upcoming challenges. The collection aims to produce a resource for academics, professionals, and the general population.
Brief Research Report articles present original research and/or preliminary findings in a more succinct way, and with fewer details, than Original Research articles. Additionally, in line with the Frontiers ethos of publishing scientifically-sound discoveries, Brief Research Reports also encourage the submission of negative results and may report on the non-reproducibility of previously published results. Brief Research Reports articles are peer-reviewed, have a maximum word count of 4,000, and may contain no more than 4 Figures/Tables. These submissions aim to highlight unique findings to produce a succinct resource as a valuable tool for researchers.
This Research Topic will only accept Brief Research Report submissions within the field of Experimental Pharmacology and Drug Discovery; reports must be original with the aim to significantly advance the field to be considered. Topics could include, but are not limited, to the following:
1. mechanisms of drug action of approved and/or potential drug candidates, looking at interactions with receptors and/or other specific biological targets (including enzymes, ion channels, transporters, transcription factors etc.),
2. drug-biomolecule interactions of approved and/or potential drug candidates (including analysis of binding, transduction mechanisms, physiological responses, and pharmacokinetics at the molecular, cellular and organism levels),
3. modern drug discovery with respect to “small molecules” and biopharmaceuticals, such as target identification (high-throughput) screening and other lead-finding techniques, medicinal chemistry, pharmacokinetics, metabolism, and pharmacology of investigatory drugs, as well as
4. novel pharmacodynamic and pharmacokinetic mechanisms that may explain/predict clinical effects of approved drugs.
